Figure 3.

A–F) Cardiac fibrosis in the transgenic heart, both untreated (A–C) and treated with ANG II (D–F), was attenuated by the Rho kinase inhibitor Fasudil. Significant decreases in collagen depositions (A, D; Sirius red staining) and fibrotic factors were observed after Fasudil treatment in the transgenic hearts analyzed by qPCR (B, E) and immunoblot analysis (C, F). qPCR data were pooled from 10 mice/group with triplicate analyses for each mouse. G) Quantification of fibrotic area over total analyzed heart area. *P < 0.001 vs. water-treated group; **P < 0.001 vs. ANG II-treated group.